Virtu Financial LLC Purchases 556 Shares of Johnson & Johnson (NYSE:JNJ)

Virtu Financial LLC increased its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 2.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,404 shares of the company’s stock after acquiring an additional 556 shares during the period. Virtu Financial LLC’s holdings in Johnson & Johnson were worth $3,444,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after acquiring an additional 3,358,478 shares in the last quarter. BlackRock Inc. grew its position in Johnson & Johnson by 0.4% in the first quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after acquiring an additional 777,837 shares in the last quarter. Wellington Management Group LLP grew its position in Johnson & Johnson by 0.8% in the first quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after acquiring an additional 265,330 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 1.6% during the first quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock valued at $5,683,837,000 after buying an additional 509,818 shares during the period. Finally, FMR LLC boosted its position in shares of Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the period. Hedge funds and other institutional investors own 68.59% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Atlantic Securities dropped their target price on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a research report on Wednesday, October 19th. Sanford C. Bernstein dropped their target price on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Raymond James dropped their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Morgan Stanley dropped their target price on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 19th. Finally, Credit Suisse Group assumed coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price for the company. Seven analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Stock Up 1.1 %

Shares of NYSE JNJ opened at $178.00 on Thursday. The firm has a market capitalization of $465.38 billion, a price-to-earnings ratio of 24.79, a PEG ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The stock has a 50 day moving average price of $169.47 and a 200 day moving average price of $171.28.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.60 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.54%. The ex-dividend date of this dividend is Monday, November 21st. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Johnson & Johnson declared that its Board of Directors has initiated a share repurchase program on Wednesday, September 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 1.2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Insider Buying and Selling

In related news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction that occurred on Friday, November 18th. The shares were sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,707,775. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,707,775. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the transaction, the executive vice president now directly owns 126,456 shares in the company, valued at $22,354,891.68. The disclosure for this sale can be found here. Insiders sold 212,646 shares of company stock valued at $36,791,022 over the last 90 days. Corporate insiders own 0.35% of the company’s stock.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Read More

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.